𝔖 Bobbio Scriptorium

✦ LIBER ✦

Amantadine for chronic hepatitis C: a magic bullet or yet another dead duck?

✍ Scribed by Antonio Craxı̀; Oreste Lo Iacono

Book ID: 119526700
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 69 KB
Volume: 35
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(01)00184-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lamivudine for chronic hepatitis B: The

Lamivudine for chronic hepatitis B: The magic bullet or just another bright prospect?

✍ Kris V. Kowdley 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 21 KB

Protease inhibitors for treatment of chr

Protease inhibitors for treatment of chronic hepatitis C—a new target for the magic bullet identified

✍ Peter Ferenci 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 104 KB

A randomized trial of induction doses of

A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C

✍ Annagiulia Gramenzi; Pietro Andreone; Carmela Cursaro; Gabriella Verucchi; Sergi 📂 Article 📅 2007 🏛 Springer Japan 🌐 English ⚖ 142 KB

Induction doses of interferon-α-2a in co

Induction doses of interferon-α-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial

✍ J. Salmerón; M. Diago; R. Andrade; R. Pérez; R. Solá; M. Romero; M. De La Mata; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 542 KB

Kinetics of soluble tumour necrosis fact

Kinetics of soluble tumour necrosis factor (TNF)-α receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-α alone, IFN-α plus amantadine or plus ribavirin

✍ F. TORRE; S. ROSSOL; N. PELLI; M. BASSO; A. DELFINO; A. PICCIOTTO 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

Interferon alfa-2A (IFN) and amantadine

Interferon alfa-2A (IFN) and amantadine (A) or placebo (P) in IFN-naive patients with chronic hepatitis C (CHC): a doouble-blind, randomized, placebo-controlled trial (SASL 8): B Helbling, R Hermann, I Stamenic, University Hospital Zurich, Zurich Switzerland; F Viani, Jj Gonvers, University Hospital Lausanne, Lausanne Switzerland; Jf Dufour, J Reichen, University Hospital Bern, Bern Switzerland; G Cathomas, University Hospital Zurich, Zurich Switzerland; M Steuerwald, University Hospital Basel, Basel Switzerland; J Borovicka, Cantonal Hosp St Gallen, St Gallen Switzerland; El Renner, University Hospital Zurich, Zurich Switzerland; and the Investigators of the Swiss Assoc for the Study of the Liver (SASL), Switzerland

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB